Streetbeat News

Analyst Ratings

CI

Eight financial analysts have recently shared their insights on Cigna Group (NYSE:CI), with opinions ranging from bullish to bearish. The average 12-month price target for CI is $348.25, with a high estimate of $372.00 and a low estimate of $327.00, marking a slight increase from the previous average of $347.00. Analyst actions include ratings from 'Buy' to 'Sector Perform' with adjustments to price targets. Cigna, a major player in health insurance and pharmacy benefit management, shows strong market performance with a notable revenue growth rate of 8.46% and impressive profitability metrics such as a net margin of 2.87% and ROE of 3.09%.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 6:01 pm

SEIC

Analyst ratings for SEI Investments (NASDAQ:SEIC) show varied opinions, with recent adjustments leading to an increased average 12-month price target of $67.75. SEI Investments, a provider of investment services, has shown impressive revenue growth and ROE, despite a market cap below industry average and a net margin below industry standards. The company's debt management is strong, with a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 6:00 pm

NVO

Four analysts have recently rated Novo Nordisk (NYSE:NVO) as somewhat bullish, with no change in sentiment over the last three months. The average 12-month price target for NVO has increased by 10% to $123.75, with adjustments from analysts at Cantor Fitzgerald and TD Cowen raising their targets. Novo Nordisk, a leader in diabetes care, has shown strong financial performance with a 28.89% revenue growth rate, a net margin of 38.27%, and an ROE of 24.5%, outperforming industry averages.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 6:00 pm

SEIC

Oppenheimer analyst Owen Lau maintains an Outperform rating on SEI Investments (NASDAQ:SEIC) and raises the price target from $71 to $73.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 5:56 pm

SRDX

Needham analyst Mike Matson maintains a Buy rating on Surmodics (NASDAQ:SRDX) and raises the price target from $44 to $47.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 5:54 pm

EVER

EverQuote's stock price increased following B. Riley Securities' decision to maintain a Buy rating and raise its price target from $14 to $18.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 5:54 pm

ROP

Oppenheimer analyst Christopher Glynn has reiterated an Outperform rating on Roper Technologies (NASDAQ:ROP) and maintained a price target of $580.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 5:54 pm

ROK

Oppenheimer analyst Noah Kaye maintains an Outperform rating on Rockwell Automation (NYSE:ROK) but lowers the price target from $324 to $300.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 5:52 pm

PTC

Oppenheimer analyst Ken Wong has maintained an Outperform rating on PTC (NASDAQ:PTC) and increased the price target from $190 to $210.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 5:49 pm

NYCB

New York Community Bancorp Inc (NYSE:NYCB) shares dropped after Q4 results missed estimates, leading to several analyst downgrades. The bank reported lower-than-expected revenue and an adjusted EPS loss, alongside a significant provision for loan losses and a dividend cut. Analysts have adjusted their price targets and ratings due to concerns over the bank's CRE exposure, increased liquidity and compliance needs, and the impact of crossing the $100 billion asset mark.

Portfolio Pulse from Lekha Gupta

February 01, 2024 | 5:49 pm